In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for ...

Exploring two complex cases of recurrent C. difficile infections unresponsive to antibiotics and FMT, and how naturopathic interventions supported long-term remission and restored quality of life. The ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Learn smart ways to save plus get daily chances to win gift cards ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

FAECAL microbiota transplant (FMT) and emerging microbiome therapeutics show clear superiority over antibiotics for recurrent Clostridium difficile infection (rCDI), according to a new systematic ...

Clinical cure and no disease recurrence within 60 days for 66.7 percent in FMT group, 61.2 percent in vancomycin group. (HealthDay News) — Fecal microbiota transplantation (FMT) could be considered as ...

Clinical cure and no disease recurrence within 60 days without additional treatment was observed in 66.7% of 51 patients receiving fecal microbiota transplantation for Clostridioides difficile ...

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) ...

1. In this randomized controlled trial, a higher proportion of patients who underwent fecal microbiota transplantation achieved clinical cure of primary Clostridioides difficile infection without ...

The pathogen C. diff -- the most common cause of health care-associated infectious diarrhea -- can use a compound that kills the human gut's resident microbes to survive and grow, giving it a ...